Strontium Ranelate Has Durable Bone Protection : Ten years of use gives one the chance to return bone turnover to premenopause levels.

The researchers matched two TROPOS placebo-group women with each woman in the extension study, assembling a total of 458 controls.

The incidence of vertebral fractures during years 5–10 in the women on strontium ranelate was 21%, compared with a 28% rate in the rebuilt control group, a statistically significant difference.

In addition, the 21% reduction during the 5 to 10- year period was statistically similar to the 19% vertebral fracture rate among women treated during 0–5 years in SOTI.

The incidence of nonvertebral fractures during years 5–10 with strontium ranelate was 14%, significantly less than the 20% rate in the derived placebo group and statistically similar to the 13% rate seen in TROPOS, Dr. Reginster reported.